Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data.
It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms.
The market opens at 10am (eastern time) and the data is taken at 10:15am, once every ASX stock has started trading.
WINNERS
Stocks highlighted in yellow made market-moving announcements (click headings to sort).
| Security | Description | Last | % | Volume | MktCap |
|---|---|---|---|---|---|
| RGS | Regeneus Ltd | 0.01 | 100% | 5,766,104 | $1,532,185 |
| OSL | Oncosil Medical | 0.007 | 40% | 16,165,111 | $11,277,706 |
| HCD | Hydrocarbon Dynamic | 0.004 | 33% | 255,000 | $2,425,747 |
| EXR | Elixir Energy Ltd | 0.094 | 32% | 13,280,029 | $80,418,171 |
| BIT | Biotron Limited | 0.098 | 31% | 20,222,376 | $67,670,663 |
| HASR | Hastings Tech Met - Rights 17-Apr-24 Def | 0.024 | 26% | 27,953 | $1,168,842 |
| SLM | Solismineralsltd | 0.12 | 20% | 893,409 | $7,807,725 |
| ESR | Estrella Res Ltd | 0.006 | 20% | 166,666 | $8,796,859 |
| EXL | Elixinol Wellness | 0.007 | 17% | 101,015 | $7,594,459 |
| SIX | Sprintex Ltd | 0.015 | 15% | 250,000 | $6,114,046 |
Clinical-stage regenerative medicine stock Regeneus (ASX:RGS) is up 120% at the open after completing its merger with Cambium Medical Technologies.
RGS will change its name and code to Cambium Bio (ASX:CMB).
Biotron (ASX:BIT) announces “positive outcomes” in a Phase 2 clinical trial of the company’s lead antiviral drug BIT225 targeting HIV.
“The results suggest that BIT225 is having a unique effect beyond that seen with current standard of care antiretroviral drugs,” it says.
Elixir Energy (ASX:EXR) is getting some impressive initial flow test results — 1.3 million cubic feet per day without stimulation — from the Grandis gas project in Queensland.
“Elixir understands this is the deepest unstimulated flow of gas in onshore Australia East of the Perth Basin,” it says.
Explorer OAR Resources (ASX:OAR) raises $1m to explore for uranium in Namibia and Brazil.
And pancreatic cancer treatment device company OncoSil Medical (ASX:OSL) continues to expand, with the first Austria-based patients receiving treatments involving the OncoSil device.
LOSERS
Stocks highlighted in yellow made market-moving announcements (click headings to sort).
| Code | Company | Price | % | Volume | Market Cap |
|---|---|---|---|---|---|
| AEV | Avenira Limited | 0.004 | -56% | 30,980,684 | $19,733,144 |
| CHK | Cohiba Min Ltd | 0.002 | -33% | 213,333 | $10,764,733 |
| LPD | Lepidico Ltd | 0.003 | -25% | 11,427,539 | $30,553,232 |
| MSI | Multistack Internat. | 0.004 | -20% | 181 | $681,520 |
| PRX | Prodigy Gold NL | 0.002 | -20% | 12,000 | $4,852,353 |
| VML | Vital Metals Limited | 0.004 | -20% | 2,213,560 | $29,475,335 |
| RR1 | Reach Resources Ltd | 0.0025 | -17% | 137,615 | $9,836,169 |
| OAU | Ora Gold Limited | 0.006 | -14% | 712,290 | $40,642,006 |
| BVR | Bellavistaresources | 0.125 | -14% | 120,859 | $7,193,591 |
| ADG | Adelong Gold Limited | 0.0035 | -13% | 250,000 | $3,521,956 |